…he theoretical potential benefits of ACTH are reflected in new studies, the availability of a depot preparation could have practical delivery advantages in the community in comparison to IVMP. NeuroSens Survey This poll is currently disabled. Back to top…
…ARL) found that ARR was significantly lower in fingolimod-treated patients compared to those treated with interferons or glatiramer acetate (Duerr et al. AAN 2015; abstract P3.253). In the two-year extension of the CARE-MS I trial, which compared alemtuzumab and subcutaneous interferon-beta-1a in treatment-naïve patients, ARR was reduced 69% when the high-dose interferon-beta cohort was switched to alemtuzumab (Hartung et al. AAN 2015; abstract P7…
…TOPIC (HR 0.660). About 57% of teriflunomide-treated patients were relapse-free in TEMSO and TOWER compared to about 46% of patients in the placebo group. A separate post-hoc analysis of TEMSO and TOWER reported that teriflunomide 14 mg was significantly more effective then placebo in reducing severe relapses defined according to different criteria (Macdonell et al. AAN 2015; abstract P7.212). In TEMSO, there was a 59% reduction in relapses leadin…
…66:561-567; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC2391073/pdf/nihms44448.pdf; Gao et al. Am J Epidemiol 2008;167:831-838; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC2367211/pdf/nihms-44283.pdf). These findings were supported by the observation of a lower PD risk in patients with gout (De Vera et al. Arthritis Rheum 2008;59:1549-1554, free full text at http://onlinelibrary.wiley.com/doi/10.1002/art.24193/pdf). A recent…
…. AAN 2015; abstract P7.223). The proportion of patients remaining relapse-free was higher in the 14-mg group compared to the 7-mg group (51.5% vs. 39.5%). EDSS changes were minimal at 528 weeks of therapy. Drug tolerability during long-term therapy was comparable to that seen in clinical trials. No new safety issues have emerged. Dimethyl fumarate: In ENDORSE, the extension of the two phase III trials of DMF, the annualized relapse rates (ARR) re…